72 related articles for article (PubMed ID: 8095806)
41. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Oncology; 1996; 53(4):263-8. PubMed ID: 8692528
[TBL] [Abstract][Full Text] [Related]
42. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
[TBL] [Abstract][Full Text] [Related]
43. Alterations in circulating lymphocyte number and function after circulation through colorectal carcinomas.
Rigg KM; Shenton BK; Brotherick I; Taylor RM; Lennard TW
Surgery; 1991 Jun; 109(6):747-55. PubMed ID: 2042094
[TBL] [Abstract][Full Text] [Related]
44. Phase IB study on prevention of surgery-induced immunodeficiency with preoperative administration of low-dose subcutaneous interleukin-2 in gastric cancer patients.
Cerea K; Romano F; Bravo AF; Motta V; Uggeri F; Brivio F; Fumagalli LA; Uggeri F
J Surg Oncol; 2001 Sep; 78(1):32-7. PubMed ID: 11519066
[TBL] [Abstract][Full Text] [Related]
45. Treatment of patients with disseminated colorectal cancer with recombinant human alpha 2-interferon. Studies on the immune system.
Einhorn S; Wasserman J; Lundell G; Blomgren H; Cedermark B; Jarstrand C; Petrini B; Strander H; Theve T; Ohman U
Int J Cancer; 1984 Feb; 33(2):251-6. PubMed ID: 6229496
[TBL] [Abstract][Full Text] [Related]
46. Preoperative lymphocyte subsets and infectious complications after colorectal cancer surgery.
Tartter PI
Surgery; 1988 Feb; 103(2):226-30. PubMed ID: 3257590
[TBL] [Abstract][Full Text] [Related]
47. [Immunological studies on colorectal cancer].
Funamoto M
Nihon Geka Hokan; 1986 May; 55(3):442-51. PubMed ID: 3800542
[No Abstract] [Full Text] [Related]
48. [Preoperative treatment with interleukin-2 in colorectal carcinoma].
Vecchio R; Latteri F; Di Martino M; Lanteri E; Cacciola E
G Chir; 1998 Apr; 19(4):171-4. PubMed ID: 9628067
[TBL] [Abstract][Full Text] [Related]
49. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer.
Tartter PI; Steinberg B; Barron DM; Martinelli G
Arch Surg; 1987 Nov; 122(11):1264-8. PubMed ID: 3675190
[TBL] [Abstract][Full Text] [Related]
50. Leukocyte adherence inhibition, natural killer cell activity, gamma-interferon production capacity and phytohemagglutinin response in patients treated with recombinant leukocyte A interferon.
Tank B; Bijma AM; Marquet RL; Eggermont AM; Weimar W; Jeekel J; Westbroek DL
Oncology; 1985; 42(3):157-63. PubMed ID: 3923413
[TBL] [Abstract][Full Text] [Related]
51. Effect of interleukin-2 on the manifestation and growth of acetoxymethyl-methylnitrosamine-induced colorectal rat adenocarcinoma.
Garzon FT; Salas M; Berger MR; Kirchner H
J Cancer Res Clin Oncol; 1986; 111(1):79-81. PubMed ID: 3485102
[TBL] [Abstract][Full Text] [Related]
52. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
Tumori; 1992 Dec; 78(6):383-7. PubMed ID: 1297233
[TBL] [Abstract][Full Text] [Related]
53. Influence of schedule on the therapeutic efficacy of chemoimmunotherapy with doxorubicin and interleukin-2.
Lumsden AJ; Codde JP; Gray BN
Biotherapy; 1992; 5(2):113-8. PubMed ID: 1524951
[TBL] [Abstract][Full Text] [Related]
54. Recombinant leukocyte A interferon as single agent therapy or in combination with cimetidine in patients with advanced colo-rectal carcinoma. A phase II investigation.
Flodgren P; Hugander A; Sjögren HO
Acta Radiol Oncol; 1985; 24(1):25-34. PubMed ID: 2984899
[TBL] [Abstract][Full Text] [Related]
55. High dose rDNA human alpha 2 interferon therapy in patients with advanced colorectal adenocarcinoma: a phase II study.
Lundell G; Blomgren H; Cedermark B; Silfverswärd C; Theve T; Ohman U
Radiother Oncol; 1984 Mar; 1(4):325-32. PubMed ID: 6505269
[TBL] [Abstract][Full Text] [Related]
56. Active specific immunotherapy for metastatic colorectal carcinoma: phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha.
Woodlock TJ; Sahasrabudhe DM; Marquis DM; Greene D; Pandya KJ; McCune CS
J Immunother; 1999 May; 22(3):251-9. PubMed ID: 10335485
[TBL] [Abstract][Full Text] [Related]
57. Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopenia.
Brivio F; Lissoni P; Fumagalli L; Brivio O; Lavorato F; Rescaldani R; Conti A; Roselli M; Maestroni G; Barni S
Oncol Rep; 1995 Jul; 2(4):597-9. PubMed ID: 21597783
[TBL] [Abstract][Full Text] [Related]
58. In vitro adsorption of colon cancer sera over staphylococcus protein A: lymphocyte stimulation by leakage of adsorbance.
Richner J; Schuff-Werner P; Bätge R; Beyer JH; Nagel GA
Klin Wochenschr; 1987 Apr; 65(8):353-8. PubMed ID: 2953935
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
Whittington R; Faulds D
Drugs; 1993 Sep; 46(3):446-514. PubMed ID: 7693434
[TBL] [Abstract][Full Text] [Related]
60. Effects of a preoperative course of interleukin-2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study.
Brivio F; Lissoni P; Barni S; Tancini G; Ardizzoia A; Erba L; Alderi G; Nociti V
Eur J Surg; 1993 Jan; 159(1):43-7. PubMed ID: 8095806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
